HEV IgG; HEV IgM
Back to Test Catalogue
Hepatitis E Virus (HEV) Antibodies IgG and IgM, Serum
Test ID: HEVAB S
Test
Method
ELISA
Report Includes
Specimens
Serum
Clinical Utility
Hepatitis E virus (HEV) is the major etiologic agent of enterically transmitted non-A, non-B hepatitis worldwide and has a high case-fatality rate in pregnant women. Both IgM and IgG antibody to HEV (anti-HEV) are produced following infection. The titer of IgM anti-HEV declines rapidly during early convalescence; IgG anti-HEV persists and appears to provide at least short-term protection against disease.
Test Location
Quest Diagnostics, California USA
Test Version
1-Mar-2023
Specimen
Specimens
Serum
Collection Containers
Gold top (clot activator & gel)
Sample Volume
1 mL
Minimum Volume
0.2 mL
Collection & Handling
Handling Information
Store and send cold or frozen.
Stability
| Ambient | 7 days |
|---|---|
| Refrigerated | 14 days |
| Frozen | 30 days |
Test Version
1-Mar-2023
Performance / Interpretation
Method
ELISA
Turnaround Time
10 days
Results
| Name | Units | Reference Range | Conversion Factor | |
|---|---|---|---|---|
| HEV IgG |
|
|||
| HEV IgM |
|
|||
|
Hepatitis E virus (HEV) is a major cause of enteric non-A hepatitis worldwide. Both HEV IgM and IgG are typically detected within one month after infection; IgM persists for about two months, whereas IgG levels persist for months to years after recovery. Approximately 20% of the US population is positive for HEV IgG, indicating that HEV exposure is more common than previously thought. |
||||
Test Location
Quest Diagnostics, California USA
Test Version
1-Mar-2023
Interface / Setup
HL7 Interface Codes
| Order Code | Result Codes | Units |
|---|---|---|
| HEVAB | 63055HEV IGG | |
| 63056HEV IGM |
Test Version
1-Mar-2023